Clinical Trials Browser

INDUSTRY × Temozolomide × Gastrointestinal × Clear all

NCT05417594 2026-03-12

CERTIS1

Phase 1/2 Recruiting

BreastCNSGastrointestinalGenitourinaryGynecologic

Astrocytoma, Breast Neoplasms, Fallopian Tube Neoplasms, Glioma, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms

NCT04337177 2025-09-23

Flavored, Oral Irinotecan VAL-413 (Orotecan®) Given With Temozolomide for Treatment of Recurrent Pediatric Solid Tumors

Phase 1 Recruiting

CNSGastrointestinalSarcoma

Medulloblastoma, Neuroblastoma, Recurrence, Rhabdomyosarcoma, Sarcoma, Ewing, Hepatoblastoma

NCT04919226 2025-09-10

COMPOSE

Phase 3 Active not recruiting

EndocrineGastrointestinalNET

Gastro-enteropancreatic neuroendocrine tumor, Neuroendocrine Tumors

NCT02231762 2019-05-06

SONNET

Phase 2 Completed

57 enrolled 20 charts

EndocrineGastrointestinalNET

Gastroenteropancreatic Neuroendocrine Tumors

NCT03607643 2018-07-31

A Study of the Efficacy of Cannabidiol in Patients With Multiple Myeloma, Glioblastoma Multiforme, and GI Malignancies

Phase 1/2 Unknown

CNSGastrointestinalPlasma cell

Colonic Neoplasms, Gallbladder Neoplasms, Glioblastoma, Liver Neoplasms, Multiple Myeloma, Pancreatic Neoplasms, Rectal Neoplasms

NCT00526617 2017-11-21

A Phase I Study of ABT-888 in Combination With Temozolomide in Cancer Patients

Phase 1 Completed

BreastDermatologicGastrointestinalGynecologic

Breast Neoplasms, Fallopian Tube Neoplasms, Carcinoma, Hepatocellular, Melanoma, Ovarian Neoplasms